Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) have earned an average rating of “Buy” from the five analysts that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $16.00.

A number of research analysts recently issued reports on TENX shares. StockNews.com assumed coverage on shares of Tenax Therapeutics in a report on Thursday, September 26th. They issued a “sell” rating for the company. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, October 24th. William Blair began coverage on Tenax Therapeutics in a research report on Monday, September 30th. They set an “outperform” rating for the company. Leerink Partners assumed coverage on Tenax Therapeutics in a research report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 price target on the stock. Finally, Guggenheim started coverage on Tenax Therapeutics in a research report on Monday, October 14th. They set a “buy” rating and a $16.00 price objective for the company.

Institutional Trading of Tenax Therapeutics

A number of large investors have recently bought and sold shares of TENX. Sphera Funds Management LTD. acquired a new stake in shares of Tenax Therapeutics during the 3rd quarter worth approximately $101,000. Stonepine Capital Management LLC acquired a new stake in Tenax Therapeutics in the third quarter worth $173,000. Finally, Vestal Point Capital LP bought a new stake in Tenax Therapeutics in the third quarter valued at $288,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

Tenax Therapeutics Trading Down 0.8 %

Tenax Therapeutics stock opened at $4.83 on Tuesday. The stock has a 50-day moving average price of $4.02 and a two-hundred day moving average price of $3.70. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $33.44.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.